VANCOUVER, BC, March 29, 2023 /PRNewswire/ - Apex Labs Ltd. (APEX or the Company), a pharmaceutical company optimizing the standard of mental health care with clinically proven psilocybin treatments, is pleased to announce the completion of the first-ever take home microdose psilocybin clinical trial, meeting all endpoints over a two month period with no adverse events. STEP-52 (risk mitigation study evaluating take home synthetic psilocybin) was specifically designed to evaluate the safety, efficacy, and tolerability of APEX-52 for the treatment of depression in patients diagnosed with Post Traumatic Stress Disorder (PTSD) within the Veteran community. The study also evaluated the stability of symptoms when transitioning from illicit unregulated psilocybin to regulated APEX-52 synthetic psilocybin.
VANCOUVER, BC, Jan. 18, 2023 /PRNewswire/ - Apex Labs Ltd. (APEX or the Company), a pharmaceutical company optimizing the standard of mental health care with psilocybin, is pleased to announce the commencement of patient dosing in APEX-002-A01-02, a phase 2b take home multi-dose psilocybin clinical trial approved in October of 2022 by Health Canada. The trial will evaluate APEX-52 (psilocybin) in treating depression and anxiety in diagnosed Post Traumatic Stress Disorder (PTSD) within the Veteran community.